TrialHeadache2019

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.

Russell Nichols et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.